MIRXES-B Shares Surge Over 35% in Afternoon Trading on Strong Industry Recognition for Non-Invasive Stomach Cancer Early Screening

Stock News03-30

MIRXES-B (02629) experienced a significant surge of over 35% during afternoon trading. At the time of writing, the stock was up 32.99%, trading at HK$16.73, with a turnover of HK$498 million. The catalyst for this movement appears to be positive industry reception. The 23rd China International Medical Examination & Blood Transfusion Equipment and Reagents Expo (CACLP) concluded successfully on March 23rd at the Xiamen International Expo Center. MIRXES emerged as a highlight of the event, showcasing its leading miRNA detection technology and specialized early cancer screening solutions. Particular attention was drawn to its core product, MiRXES' GASTROClear™. It is reported that the product has completed prospective clinical validation involving nearly ten thousand individuals, demonstrating excellent detection performance. The product has already received approval in multiple countries and regions, including Singapore, China, and the European Union, addressing a significant gap in the market for non-invasive stomach cancer early screening. Furthermore, in late February, MIRXES announced the signing of a memorandum of understanding with Apollo Health and Lifestyle, a wholly-owned subsidiary of India's Apollo Group. The companies intend to jointly develop and commercialize advanced early cancer screening solutions in India and surrounding countries, with plans to establish a joint venture valued at no less than $50 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155445768?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 14:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155445768","market":"fut","top_or_hot":-1,"title":"MIRXES-B Shares Surge Over 35% in Afternoon Trading on Strong Industry Recognition for Non-Invasive Stomach Cancer Early Screening","media":"Stock News","content":"<p>MIRXES-B (02629) experienced a significant surge of over 35% during afternoon trading. At the time of writing, the stock was up 32.99%, trading at HK$16.73, with a turnover of HK$498 million. The catalyst for this movement appears to be positive industry reception. The 23rd China International Medical Examination & Blood Transfusion Equipment and Reagents Expo (CACLP) concluded successfully on March 23rd at the Xiamen International Expo Center. MIRXES emerged as a highlight of the event, showcasing its leading miRNA detection technology and specialized early cancer screening solutions. Particular attention was drawn to its core product, MiRXES' GASTROClear™. It is reported that the product has completed prospective clinical validation involving nearly ten thousand individuals, demonstrating excellent detection performance. The product has already received approval in multiple countries and regions, including Singapore, China, and the European Union, addressing a significant gap in the market for non-invasive stomach cancer early screening. Furthermore, in late February, MIRXES announced the signing of a memorandum of understanding with Apollo Health and Lifestyle, a wholly-owned subsidiary of India's Apollo Group. The companies intend to jointly develop and commercialize advanced early cancer screening solutions in India and surrounding countries, with plans to establish a joint venture valued at no less than $50 million.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MIRXES-B Shares Surge Over 35% in Afternoon Trading on Strong Industry Recognition for Non-Invasive Stomach Cancer Early Screening</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMIRXES-B Shares Surge Over 35% in Afternoon Trading on Strong Industry Recognition for Non-Invasive Stomach Cancer Early Screening\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-30 14:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MIRXES-B (02629) experienced a significant surge of over 35% during afternoon trading. At the time of writing, the stock was up 32.99%, trading at HK$16.73, with a turnover of HK$498 million. The catalyst for this movement appears to be positive industry reception. The 23rd China International Medical Examination & Blood Transfusion Equipment and Reagents Expo (CACLP) concluded successfully on March 23rd at the Xiamen International Expo Center. MIRXES emerged as a highlight of the event, showcasing its leading miRNA detection technology and specialized early cancer screening solutions. Particular attention was drawn to its core product, MiRXES' GASTROClear™. It is reported that the product has completed prospective clinical validation involving nearly ten thousand individuals, demonstrating excellent detection performance. The product has already received approval in multiple countries and regions, including Singapore, China, and the European Union, addressing a significant gap in the market for non-invasive stomach cancer early screening. Furthermore, in late February, MIRXES announced the signing of a memorandum of understanding with Apollo Health and Lifestyle, a wholly-owned subsidiary of India's Apollo Group. The companies intend to jointly develop and commercialize advanced early cancer screening solutions in India and surrounding countries, with plans to establish a joint venture valued at no less than $50 million.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1155445768","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155445768","pubTimestamp":1774851505,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MIRXES-B (02629) experienced a significant surge of over 35% during afternoon trading. At the time of writing, the stock was up 32.99%, trading at HK$16.73, with a turnover of HK$498 million. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","02629":"MIRXES-B","VXUS":"国际股票ETF-Vanguard"},"translate_title":"由于行业对非侵入性胃癌早期筛查的强烈认可，MIRXES-B股价在下午交易中飙升超过35%","themeId":"7a893e01b81c1c9b5ce05de92043a19d","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02629":1},"content_text":"MIRXES-B (02629) experienced a significant surge of over 35% during afternoon trading. At the time of writing, the stock was up 32.99%, trading at HK$16.73, with a turnover of HK$498 million. The catalyst for this movement appears to be positive industry reception. The 23rd China International Medical Examination & Blood Transfusion Equipment and Reagents Expo (CACLP) concluded successfully on March 23rd at the Xiamen International Expo Center. MIRXES emerged as a highlight of the event, showcasing its leading miRNA detection technology and specialized early cancer screening solutions. Particular attention was drawn to its core product, MiRXES' GASTROClear™. It is reported that the product has completed prospective clinical validation involving nearly ten thousand individuals, demonstrating excellent detection performance. The product has already received approval in multiple countries and regions, including Singapore, China, and the European Union, addressing a significant gap in the market for non-invasive stomach cancer early screening. Furthermore, in late February, MIRXES announced the signing of a memorandum of understanding with Apollo Health and Lifestyle, a wholly-owned subsidiary of India's Apollo Group. The companies intend to jointly develop and commercialize advanced early cancer screening solutions in India and surrounding countries, with plans to establish a joint venture valued at no less than $50 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155445768","isCrawlerRequest":true}